AI Article Synopsis
- This study aimed to assess the effectiveness of combining intra-arterial 5-fluorouracil (5-FU), subcutaneous interferon (IFN), and image-guided radiation therapy (IGRT) in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).
- The research involved two groups: one receiving the combination therapy (IGRT group) and the other receiving 5-FU and IFN alone (non-IGRT group), with comparisons made on overall survival, response rates, and time to progression.
- Results showed that the IGRT group had significantly better response rates and overall median survival (12.0 months) compared to the non-IGRT
Article Abstract
Background And Aim: To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).
Methods: Twenty HCC patients with PVTT were treated with 5-FU and IFN combined with image-guided radiation therapy (IGRT) (IGRT group), and as controls, 20 patients with PVTT were treated with 5-FU and IFN alone (non-IGRT group). Overall survival (OS) time, response rates, time to progression (TTP) and safety were compared across groups.
Results: Complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) of PVTT were 5%, 55%, 40% and 0% in the IGRT group and 0%, 30%, 35% and 35%, in the non-IGRT group, respectively. CR, PR, SD, and PD of the whole tumor were 0%, 35%, 45% and 20% in the IGRT group and 0%, 30%, 35% and 35%, in the non-IGRT group, respectively. Overall median survival was significantly longer in the IGRT group (12.0 months 95% confidence interval [CI], 9.3-17.6 months) than in the non-IGRT group (9.1 months [95% CI, 5.5-11.1 months]) (P = 0.041). TTP was significantly longer in the IGRT group (6.9 months [95% CI, 5.6-10.2 months]) than in the non-IGRT group (4.0 months [95% CI, 3.3-6.4 months]) (P = 0.034).
Conclusions: The response rates, median OS time and TTP in patients with advanced HCC with PVTT who received this novel combination therapy of intra-arterial 5-FU and subcutaneous IFN with IGRT are encouraging, and this combination therapy warrants further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-1746.2011.06745.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Embracing the Future of Clinical Trials in Radiotherapy: An NRG Oncology CIRO Technology Retreat Whitepaper on Pioneering Technologies and AI-Driven Solutions.
Int J Radiat Oncol Biol Phys
January 2025
National Cancer Institute, Bethesda, MD. Electronic address:
This white paper examines the potential of pioneering technologies and artificial intelligence (AI)-driven solutions in advancing clinical trials involving radiotherapy. As the field of radiotherapy evolves, the integration of cutting-edge approaches such as radiopharmaceutical dosimetry, FLASH radiotherapy, image-guided radiation therapy (IGRT), and AI promises to improve treatment planning, patient care, and outcomes. Additionally, recent advancements in quantum science, linear energy transfer/relative biological effect (LET/RBE), and the combination of radiotherapy and immunotherapy create new avenues for innovation in clinical trials.
View Article and Find Full Text PDFImmunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction.
Allergy Asthma Clin Immunol
January 2025
Immune Deficiency Foundation, Towson, MD, USA.
Background: Immunoglobulin replacement therapy (IgRT) is the current standard of care for primary antibody deficiency patients (majority of all primary immunodeficiency (PID) diseases), with growing real-world evidence supporting use for secondary immunodeficiency (SID) patients. Infusion methods and practices can affect patients' satisfaction with their treatment and perception of their health-related quality of life.
Methods: An online survey of US patients with PID and SID was conducted.
Impact of belly board immobilization devices and body mass factor on setup displacement using daily cone-beam CT in rectal cancer radiotherapy.
J Appl Clin Med Phys
November 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Objective: The objective of this study is to evaluate the impact of different belly board and daily changes in patient's body-mass factor (BMF) on setup displacement in radiotherapy for rectal cancer.
Methods: Twenty-five patients were immobilized using the thermoplastic mask with belly board (TM-BB), and 30 used the vacuum bag cushion with belly board (VBC-BB), performing daily cone-beam computed tomography (CBCT) scans 625 times and 750 times, respectively. Daily pretreatment CBCT scans were registered to the planned CT images for BMF change determination and setup displacement measurement.
First implementation and results of online adaptive radiotherapy for cervical cancer based on CT-Linac combination.
Front Oncol
November 2024
Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
Article Synopsis
- - The study evaluates the effectiveness of online adaptive radiation therapy (oART) compared to image-guided radiation treatment (IGRT) for cervical cancer in terms of dosimetry and patient safety over time.
- - Results showed that oART improved treatment parameters, such as target coverage and reduced radiation exposure to surrounding organs, with significant differences in most metrics, indicating better dosimetric outcomes.
- - After a median follow-up of 28 months, the survival rates were promising, with a 3-year event-free survival rate of 79.4% and an overall survival rate of 92.9%, suggesting that oART is a safe and effective treatment option.
Current Practice and Perspectives on Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Antibody Deficiency Among Specialized Nurses in Poland.
Nurs Rep
November 2024
Jagiellonian University Medical College, Faculty of Medicine, Department of Internal Medicine, Jakubowskiego 2, 30-688 Kraków, Poland.
Background/objectives: Inborn errors of immunity (IEI) encompass various congenital disorders, resulting in immunity defects and recurrent infections. Home-based subcutaneous immunoglobulin replacement therapy (scIgRT) is the best treatment option for those with primary antibody deficiency (PAD). However, the lack of standardized procedures in patient training remains a challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!